Bullous systemic lupus erythematosus successfully treated with rituximab

Christopher D. Lowe, Catherine A. Brahe, Brian Philip Green, Thomas K. Lam, Jon H. Meyerle

Research output: Contribution to journalArticle

Abstract

Bullous systemic lupus erythematosus (BSLE) is a rare complication of systemic lupus erythematosus (SLE) characterized by cutaneous vesicles and bullae with a primarily neutrophilic infiltrate on histopathology. Bullous SLE is a heterogeneous disease without pathognomonic clinical features, making the diagnosis and differentiation from other blistering diseases challenging. We present the case of a single patient with SLE in whom 3 different clinical appearances of BSLE manifested over 5 years. The cutaneous eruption dramatically improved with rituximab at the initial presentation and continued to respond to rituximab during subsequent flares over the subsequent 5 years.

Original languageEnglish (US)
Pages (from-to)E5-E7
JournalCutis
Volume103
Issue number6
StatePublished - Jan 1 2019

Fingerprint

Systemic Lupus Erythematosus
Skin
Blister
Rituximab

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Lowe, C. D., Brahe, C. A., Green, B. P., Lam, T. K., & Meyerle, J. H. (2019). Bullous systemic lupus erythematosus successfully treated with rituximab. Cutis, 103(6), E5-E7.
Lowe, Christopher D. ; Brahe, Catherine A. ; Green, Brian Philip ; Lam, Thomas K. ; Meyerle, Jon H. / Bullous systemic lupus erythematosus successfully treated with rituximab. In: Cutis. 2019 ; Vol. 103, No. 6. pp. E5-E7.
@article{22b97cb6554740a1821ef0599a62da53,
title = "Bullous systemic lupus erythematosus successfully treated with rituximab",
abstract = "Bullous systemic lupus erythematosus (BSLE) is a rare complication of systemic lupus erythematosus (SLE) characterized by cutaneous vesicles and bullae with a primarily neutrophilic infiltrate on histopathology. Bullous SLE is a heterogeneous disease without pathognomonic clinical features, making the diagnosis and differentiation from other blistering diseases challenging. We present the case of a single patient with SLE in whom 3 different clinical appearances of BSLE manifested over 5 years. The cutaneous eruption dramatically improved with rituximab at the initial presentation and continued to respond to rituximab during subsequent flares over the subsequent 5 years.",
author = "Lowe, {Christopher D.} and Brahe, {Catherine A.} and Green, {Brian Philip} and Lam, {Thomas K.} and Meyerle, {Jon H.}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "103",
pages = "E5--E7",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "6",

}

Lowe, CD, Brahe, CA, Green, BP, Lam, TK & Meyerle, JH 2019, 'Bullous systemic lupus erythematosus successfully treated with rituximab', Cutis, vol. 103, no. 6, pp. E5-E7.

Bullous systemic lupus erythematosus successfully treated with rituximab. / Lowe, Christopher D.; Brahe, Catherine A.; Green, Brian Philip; Lam, Thomas K.; Meyerle, Jon H.

In: Cutis, Vol. 103, No. 6, 01.01.2019, p. E5-E7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bullous systemic lupus erythematosus successfully treated with rituximab

AU - Lowe, Christopher D.

AU - Brahe, Catherine A.

AU - Green, Brian Philip

AU - Lam, Thomas K.

AU - Meyerle, Jon H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bullous systemic lupus erythematosus (BSLE) is a rare complication of systemic lupus erythematosus (SLE) characterized by cutaneous vesicles and bullae with a primarily neutrophilic infiltrate on histopathology. Bullous SLE is a heterogeneous disease without pathognomonic clinical features, making the diagnosis and differentiation from other blistering diseases challenging. We present the case of a single patient with SLE in whom 3 different clinical appearances of BSLE manifested over 5 years. The cutaneous eruption dramatically improved with rituximab at the initial presentation and continued to respond to rituximab during subsequent flares over the subsequent 5 years.

AB - Bullous systemic lupus erythematosus (BSLE) is a rare complication of systemic lupus erythematosus (SLE) characterized by cutaneous vesicles and bullae with a primarily neutrophilic infiltrate on histopathology. Bullous SLE is a heterogeneous disease without pathognomonic clinical features, making the diagnosis and differentiation from other blistering diseases challenging. We present the case of a single patient with SLE in whom 3 different clinical appearances of BSLE manifested over 5 years. The cutaneous eruption dramatically improved with rituximab at the initial presentation and continued to respond to rituximab during subsequent flares over the subsequent 5 years.

UR - http://www.scopus.com/inward/record.url?scp=85070632156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070632156&partnerID=8YFLogxK

M3 - Article

VL - 103

SP - E5-E7

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 6

ER -

Lowe CD, Brahe CA, Green BP, Lam TK, Meyerle JH. Bullous systemic lupus erythematosus successfully treated with rituximab. Cutis. 2019 Jan 1;103(6):E5-E7.